Johnson & Johnson reports Q3 2026 results on October 13, with MedTech segment performance a key focus amid expectations for modest sequential improvement. Q2 MedTech revenue reached $8.926 billion, up 4.5% year-over-year, supported by double-digit growth at Shockwave but pressured by softer Abiomed sales and competitive intensity in electrophysiology. Analysts project Q3 MedTech around $8.77–8.78 billion, with acceleration anticipated in Surgery, Vision, and Orthopedics offsetting continued cardiovascular headwinds, including China volume-based procurement impacts and procedure selectivity. Total company revenue consensus sits near $25.37 billion, implying MedTech as roughly 35% of the mix, with traders monitoring procedure volumes, new product ramps like Ottava robotics, and any updates on Abiomed recovery for resolution signals.